🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMarketplace & ListingsPrice comparison: compounded semaglutide — 6 month update

Price comparison: compounded semaglutide — 6 month update

RickReta_CO Tue, Dec 9, 2025 at 12:09 AM 12 replies 1,200 viewsPage 1 of 3
This thread is more than 6 months old. Information may be outdated. Consider searching for more recent discussions.
RickReta_CO
Member
312
1,234
Jan 2025
Colorado
Dec 9, 2025 at 12:09 AM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Two things anyone can check: a state licence number for a 503A, and an FDA outsourcing-facility registration for a 503B. Both are publicly searchable, and a pharmacy unwilling to give you either has answered the question.

So the question, as narrowly as I can put it: why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Not looking for reassurance. Looking for the part I have got wrong.

14 9matt_MKE, Dr.ReproEndo, lucas_SP_BR and 11 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Dec 9, 2025 at 1:49 AM#2

Short answer first, then the reasoning. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

That is the short version; the long version is somebody else's post.

Last edited: Dec 9, 2025 at 2:49 AM
13 8PharmD_Rodriguez, julia.endo, JessicaM_2024 and 10 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Dec 9, 2025 at 3:29 AM#3
BenResearch_OR said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

Last edited: Dec 9, 2025 at 6:29 AM
12 7Admin, Dr.Martinez, mike_mod and 9 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Dec 9, 2025 at 5:09 AM#4
RickReta_CO said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Same position here, arrived at the long way round. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

11 6lucas_SP_BR, lisa_labSD, adam_van and 8 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Dec 9, 2025 at 2:55 PM#5

Adding the clinical framing, because it changes how the question reads.

FDA inspection results for compounding pharmacies selling compounded supply: you can look up any 503B facility's FDA inspection history on the FDA website.

Check for: Form 483 observations (violations), warning letters, and recall history. A clean inspection record is a strong indicator of quality. My pharmacy has had 0 Form 483 observations in their last 4 inspections.

This is public information. Use it. Link: fda.gov/inspections-compliance-enforcement-and-criminal-investigations

10 5claudia_zurich, nancy_portland, rick_sfbay and 7 others
Reply Quote Save Share Report

Similar Threads

Price comparison: compounded semaglutide — June 202622 replies
Telehealth provider directory — updated quarterly5 replies
Group buy discussion — is it worth organizing?3 replies
Bacteriostatic water sourcing guide — verified suppliers3 replies
Compounded semaglutide price tracker — updated weekly19 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register